Compare GSK plc (GSK) vs Lemonade Inc (LMND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Lemonade Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Lemonade Inc trades at $46.5 (market cap $3.63B). The key difference: GSK plc is far larger — about 25.3× Lemonade Inc's market cap, and GSK plc pays a 3.9% dividend while Lemonade Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Lemonade Inc for 27 Days on average.
| GSK | LMND | |
|---|---|---|
Market Cap | $91.88B | $3.63B |
Volume | 7,730,529 | 1,544,794 |
Sector | Health | Financials |
52-Week High | $61.18 | $96.57 |
52-Week Low | $43.24 | $43.91 |
Typical Hold Time | 93 Days | 27 Days |
Enterprise Value | $111.88B | $3.49B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
LMND trades at $46.46, down 0.79% on the day, with a bearish technical signal and key resistance at $48. Revenue growth is strong, rising to $738 million in 2025, but the company remains unprofitable with a net margin of -22.43%. Recent news highlights expansion into new states and AI-driven efficiency gains, targeting EBITDA profitability by late 2026.
The outlook balances high growth potential against persistent losses. Analyst consensus is divided with a $67 price target suggesting upside, but execution risks and competitive pressures remain key concerns. The path to profitability is the critical catalyst for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →
